Listed

Aptargroup, Inc.: Form 10-Q for the period ended Mar 31, 2026

Filed with the SEC on May 1, 2026 and accepted by EDGAR at May 1, 2026, 11:22 ET.

Share

Management's discussion and analysis

As filed, 46,020 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

(AMOUNTS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS, OR AS OTHERWISE INDICATED)

RESULTS OF OPERATIONS

Three Months Ended March 31, 2026 2025
Net sales 100.0% 100.0%
Cost of sales (exclusive of depreciation and amortization shown below) 64.2 62.1
Selling, research & development and administrative 17.1 17.5
Depreciation and amortization 7.7 7.4
Restructuring initiatives 0.1 0.2
Operating income 10.9 12.8
Interest expense (1.7) (1.3)
Other expense 0.3 0.4
Income before income taxes 9.5 11.9
Net Income 7.4 8.9
Effective tax rate 22.4% 25.8%
Adjusted EBITDA margin (1) 19.2% 20.7%

(1) Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation under “Non-U.S. GAAP Measures.”

NET SALES

Reported net sales for the first three months of 2026 increased 11% to $982.9 million compared to $887.3 million for the first three months of 2025. Foreign currency exchange rates and acquisitions each positively impacted our consolidated results by 8% and 3%, respectively during the first three months of 2026. Therefore, core sales, which exclude acquisitions and changes in foreign currency exchange rates, for the first three months of 2026 was flat when compared with the same period in 2025. Volume growth in our Beauty and Closures segments, along with higher tooling sales were offset by lower sales of emergency medicine products within our Pharma segment and the pass through of lower material costs.

Three Months Ended March 31, 2026 Net Sales Change over Prior Year Pharma Beauty Closures Total
Reported Net Sales Growth 7% 19% 5% 11%
Currency Effects (1) (7)% (9)% (5)% (8)%
Acquisitions (1)% (7)% —% (3)%
Core Sales Growth (1)% 3% —% —%

(1) Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

The following table sets forth, for the periods indicated, net sales by geographic location based on shipped to locations:

Three Months Ended March 31, 2026 % of Total 2025 % of Total
Domestic $279,806 28% $282,457 32%
Europe 510,850 52% 438,646 49%
Latin America 85,967 9% 72,514 8%
Asia 106,245 11% 93,688 11%

For discussion regarding net sales by reporting segment, please refer to the analysis of segment net sales and segment Adjusted EBITDA on the following pages.

COST OF SALES (EXCLUSIVE OF DEPRECIATION AND AMORTIZATION SHOWN BELOW)

For the first three months of 2026, cost of sales ("COS") as a percentage of net sales increased to 64.2% compared to 62.1% in the same period in 2025. This increase is mainly due to the lower sales of some higher margin Pharma products, and lower margins on our tooling sales compared to the first three months of 2025.

SELLING, RESEARCH & DEVELOPMENT AND ADMINISTRATIVE

Our selling, research & development and administrative ("SG&A") expenses increased by approximately $12.3 million to $167.6 million in the first three months of 2026 compared to $155.3 million during the same period in 2025. Excluding changes in foreign currency rates, SG&A increased by approximately $2.7 million in the first three months of 2026 compared to the first three months of 2025. $2.6 million of this increase relates to incremental SG&A costs in 2026 due to our acquisitions. SG&A as a percentage of net sales decreased to 17.1% in the first three months of 2026 compared to 17.5% in the same period in 2025.

DEPRECIATION AND AMORTIZATION

Depreciation and amortization expenses increased by approximately $10.1 million to $75.7 million in the first three months of 2026 compared to $65.6 million during the same period a year ago. Excluding changes in foreign currency rates, depreciation and amortization increased by approximately $5.3 million in the first three months of 2026 compared to the same period a year ago. Of this increase, $3.8 million relates to incremental depreciation and amortization costs in 2026 due to our acquisitions. The remaining net increase is due to higher capital investments made to support our growth strategy offset by certain intangible assets being fully amortized. Depreciation and amortization as a percentage of net sales increased to 7.7% in the first three months of 2026 compared to 7.4% in the same period of the prior year.

RESTRUCTURING INITIATIVES

For the three months ended March 31, 2026 and 2025, we recognized $1.1 million and $2.0 million, respectively, of restructuring costs related to initiatives to better leverage our fixed cost base through growth and cost reduction measures. The cumulative expense incurred as of March 31, 2026 was $75.6 million.

Restructuring costs for the three months ended March 31, 2026 and 2025 were as follows:

Three Months Ended March 31, Restructuring Initiatives by Segment: 2026 2025
Pharma $5 $190
Beauty 1,301 395
Closures 249 1,352
Corporate & Other (469) 105
Total Restructuring Initiatives $1,086 $2,042

OPERATING INCOME

For the first three months of 2026, operating income decreased by approximately $6.0 million to $107.5 million compared to $113.4 million in the same period of the prior year. Excluding changes in foreign currency rates, operating income decreased by approximately $15.8 million in the first three months of 2026 compared to the same period a year ago. This decrease was mainly driven by higher COS as a percentage of revenue, reflecting product mix and lower tooling margins, as well as lower sales of certain higher-margin products within our Pharma segment and higher depreciation costs to support our growth initiatives. Operating income as a percentage of net sales decreased to 10.9% in the first three months of 2026 compared to 12.8% for the same period in the prior year.

INTEREST EXPENSE

Interest expense increased approximately $5.6 million to $16.9 million in the first three months of 2026 compared to $11.4 million during the same period in 2025. Since the beginning of 2025, we have repaid $250.0 million of private placement debt having an interest rate of 3.6% and issued a total of $600.0 million in new notes with a fixed interest rate of 4.75%, thus increasing both the amount and the average interest rate of our debt in the first quarter of 2026 compared to the same period in the prior year. See Note 6 - Debt to the Condensed Consolidated Financial Statements for further details on our current debt structure.

NET OTHER INCOME (EXPENSE)

Net other income decreased approximately $0.7 million to $3.2 million of income for the three months ended March 31, 2026 from $3.9 million of income in the same period of the prior year. Higher interest income of $0.8 million was offset by approximately $1.4 million in lower equity results from affiliates in part due to our investment in BTY now being fully consolidated.

PROVISION FOR INCOME TAXES

The effective tax rate for the three months ended March 31, 2026 and 2025 was 22.4% and 25.8%, respectively. The lower effective tax rate for the three months ended March 31, 2026 reflects a more favorable mix of earnings and greater excess tax benefits from share-based compensation.

NET INCOME ATTRIBUTABLE TO APTARGROUP, INC.

We reported net income attributable to AptarGroup, Inc. of $72.7 million and $78.8 million in the three months ended March 31, 2026 and 2025, respectively.

PHARMA SEGMENT

Operations that sell proprietary dispensing systems, drug delivery systems, sealing solutions and services to the prescription drug, consumer healthcare, injectables, active material science solutions and digital health markets form our Pharma segment.

Three Months Ended March 31, 2026 2025
Net Sales $438,560 $409,467
Adjusted EBITDA (1) 146,223 142,450
Adjusted EBITDA margin (1) 33.3% 34.8%

(1) Adjusted EBITDA is calculated as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation under “Non-U.S. GAAP Measures.”

Net sales for the first three months of 2026 increased by approximately 7% to $438.6 million compared to $409.5 million in the first three months of 2025. Changes in currency rates and acquisitions positively impacted net sales by 7% and 1%, respectively during the first three months of 2026. Therefore, core sales decreased by 1% in the first three months of 2026 compared to the same period in the prior year. Strong sales in our consumer healthcare and Injectables divisions, along with higher tooling sales could not compensate for lower prescription drug sales. Core sales of products included in our prescription drug division decreased 10% mainly on difficult emergency medicine comparisons to the prior year. Core sales in the consumer healthcare market increased 4% on higher demand for our eye care and nasal decongestant products. Injectables core sales increased 20% with strong demand primarily for elastomeric components used for GLP-1, biologics and antithrombotic applications. Core sales of our active material science solutions decreased 1% as increases in sales of our oral solid dose technologies could not offset declines in probiotic product sales.

Three Months Ended March 31, 2026 Net Sales Change over Prior Year Prescription Drug (2) Consumer Health Care Injectables Active Material Science Solutions Total
Reported Net Sales Growth (4)% 20% 30% 3% 7%
Currency Effects (1) (6)% (11)% (10)% (4)% (7)%
Acquisitions —% (5)% —% —% (1)%
Core Sales Growth (10)% 4% 20% (1)% (1)%

(1) Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

(2) Prescription drug includes prescription drug and digital health solutions.

Adjusted EBITDA in the first three months of 2026 increased 3% to $146.2 million compared to $142.5 million in the same period of the prior year. This increase was mainly due to strong operational performance in the first quarter of 2026, a favorable currency impact and the core sales growth in consumer healthcare and injectables discussed above. However, due to the lower sales of our higher-margin emergency medicine products, our Adjusted EBITDA margin declined to 33.3% in the first three months of 2026 compared to 34.8% in the first three months of 2025.

BEAUTY SEGMENT

Operations that sell dispensing systems and sealing solutions to the beauty, personal care and home care markets form our Beauty segment.

Three Months Ended March 31, 2026 2025
Net Sales $363,635 $305,707
Adjusted EBITDA (1) 40,482 37,138
Adjusted EBITDA margin (1) 11.1% 12.1%

(1) Adjusted EBITDA is calculated as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation under “Non-U.S. GAAP Measures.”

For the first three months of 2026, reported net sales of $363.6 million increased 19% compared to $305.7 million reported in the first three months of the prior year. Changes in currency rates and acquisitions positively impacted net sales by 9% and 7%, respectively, in the first three months of 2026. Therefore, core sales increased 3% during the first three months of 2026 compared to the same period in the prior year. Overall, improving volumes were slightly offset by lower tooling sales and the pass through of lower material costs. Core sales of our products to the F&F market increased 3% during the first three months of 2026 due to strong demand for our prestige and masstige fragrance technologies as well as our color cosmetic products. Personal care core sales improved 6% over the prior year on higher sales of our hair care and body and skincare products. Core sales of our home care market products, which makes up a smaller percentage of our total sales, declined 12% on lower demand from our customers selling air care and surface cleaning products.

Three Months Ended March 31, 2026 Net Sales Change over Prior Year F&F (2) Personal Care Home Care Total
Reported Net Sales Growth 24% 15% 12% 19%
Currency Effects (1) (11)% (9)% (6)% (9)%
Acquisitions (10)% —% (18)% (7)%
Core Sales Growth 3% 6% (12)% 3%

(1) Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

(2) F&F includes fragrance, facial skincare and color cosmetics.

Adjusted EBITDA in the first three months of 2026 increased 9% to $40.5 million compared to $37.1 million reported in the same period in the prior year. This increase was mainly driven by improving fragrance and color cosmetic volumes mentioned above along with a favorable currency impact. However, some isolated operational issues led to our Adjusted EBITDA margin to decline from 12.1% in the first three months of 2025 to 11.1% during the first three months of 2026.

CLOSURES SEGMENT

Operations that sell dispensing closures, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and other markets form our Closures segment. Our food protection business and elastomeric flow-control technology business continue to report through the Closures segment.

Three Months Ended March 31, 2026 2025
Net Sales $180,673 $172,131
Adjusted EBITDA (1) 23,657 27,260
Adjusted EBITDA margin (1) 13.1% 15.8%

(1) Adjusted EBITDA is calculated as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation under “Non-U.S. GAAP Measures.”

Net sales for the first three months of 2026 increased approximately 5% to $180.7 million compared to $172.1 million in the first three months of 2025. Changes in currency rates positively impacted net sales by 5%. Therefore, core sales were flat in the first three months of 2026 compared to the same period in the prior year as higher product and tooling sales for the first quarter of 2026 was fully offset by the pass through of lower resin costs. Core sales to our food customers declined 3% mainly due to the resin impact noted above. Increases in sales of our products to the food service and sauce and condiment markets were offset by lower Asian sauces and granular powder product sales. Core sales to our beverage customers increased 10% during the first three months of 2026 on strong tooling sales and improving dairy and liquid coffee creamer application sales. Personal care core sales declined 12% on lower tooling sales and sales of our hair care solutions while the other markets improved by 13% on stronger sales of our laundry and dish care products.

Three Months Ended March 31, 2026 Net Sales Change over Prior Year Food Beverage Personal Care Other (2) Total
Reported Net Sales Growth 1% 17% (7)% 21% 5%
Currency Effects (1) (4)% (7)% (5)% (8)% (5)%
Core Sales Growth (3)% 10% (12)% 13% —%

(1) Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

(2) Other includes beauty, home care and other markets.

Adjusted EBITDA in the first three months of 2026 decreased 13% to $23.7 million compared to $27.3 million reported in the same period of the prior year. The positive impact of higher product sales discussed above was offset by some operational issues and a $0.9 million write-off of an equity investment. This led to our Adjusted EBITDA margin declining from 15.8% in the first three months of 2025 to 13.1% during the first three months of 2026.

CORPORATE & OTHER

In addition to our three reporting segments, we assign certain costs to “Corporate & Other” which is presented separately in Note 16 – Segment Information of the Notes to the Condensed Consolidated Financial Statements. For Corporate & Other, Adjusted EBITDA (which excludes net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items) primarily includes certain professional fees, compensation and information system costs which are not allocated directly to our reporting segments.

For the first three months of 2026, Corporate & Other costs decreased to $21.5 million compared to $23.5 million reported in the same period of the prior year. This decrease is mainly due to lower incentive compensation costs.

NON-U.S. GAAP MEASURES

In addition to the information presented herein that conforms to U.S. GAAP, we also present financial information that does not conform to U.S. GAAP, which are referred to as non-U.S. GAAP financial measures. Management may assess our financial results both on a U.S. GAAP basis and on a non-U.S. GAAP basis. We believe it is useful to present these non-U.S. GAAP financial measures because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect our core operating performance. These non-U.S. GAAP financial measures should not be considered in isolation or as a substitute for U.S. GAAP financial results, but should be read in conjunction with the unaudited Condensed Consolidated Statements of Income and other information presented herein. Investors are cautioned against placing undue reliance on these non-U.S. GAAP measures. Further, investors are urged to review and consider carefully the adjustments made by management to the most directly comparable U.S. GAAP financial measures to arrive at these non-U.S. GAAP financial measures.

In our Management’s Discussion and Analysis, we exclude the impact of foreign currency translation when presenting net sales and other information, which we define as “constant currency.” Core sales, which excludes the impact of acquisitions and foreign currency translation is a non-U.S. GAAP financial measure. Core sales growth is calculated as current-period core sales less prior period core sales divided by prior period core sales multiplied by a hundred. As a worldwide business, it is important that we take into account the effects of foreign currency translation when we view our results and plan our strategies. Consequently, when our management looks at our financial results to measure the core performance of our business, we may exclude the impact of foreign currency translation by translating our prior period results at current period foreign currency exchange rates. As a result, management believes that these presentations are useful internally and may be useful to investors. We also exclude the impact of material acquisitions when comparing results to prior periods. Changes in operating results excluding the impact of acquisitions are non-U.S. GAAP financial measures. We believe it is important to exclude the impact of acquisitions on period over period results in order to evaluate performance on a more comparable basis.

We present earnings before net interest and taxes (“EBIT”), earnings before net interest, taxes, depreciation and amortization (“EBITDA”) and adjusted earnings per share. We also present our adjusted earnings before net interest and taxes (“Adjusted EBIT”), adjusted earnings before net interest, taxes, depreciation and amortization (“Adjusted EBITDA”) and adjusted earnings per share, all of which exclude restructuring initiatives, acquisition-related costs, purchase accounting adjustments related to acquisitions and investments, net unrealized investment gains and losses related to observable market price changes on equity securities, and other special items. For the three months ended March 31, 2026, "Other special items" include costs incurred related to non-ordinary-course litigation regarding matters under "Legal Proceedings" within Note 12 - Commitments and Contingencies as these costs do not reflect our core operating performance. Our Outlook is also provided on a non-U.S. GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of our routine activities, such as restructuring initiatives, acquisition-related costs and other special items.

We provide a reconciliation of Net Debt to Net Capital as a non-U.S. GAAP measure. “Net Debt” is calculated as interest-bearing debt less cash and equivalents and short-term investments while “Net Capital” is calculated as stockholders’ equity plus Net Debt. Net Debt to Net Capital measures a company’s financial leverage, which gives users an idea of a company's financial structure, or how it is financing its operations, along with insight into its financial strength. We believe that it is meaningful to take into consideration the balance of our cash, cash equivalents and short-term investments when evaluating our leverage. If needed, such assets could be used to reduce our gross debt position.

Finally, we provide a reconciliation of free cash flow as a non-U.S. GAAP measure. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives.

Three Months Ended March 31, 2026 Consolidated Pharma Beauty Closures Corporate & Other Net Interest
Net Sales $982,868 $438,560 $363,635 $180,673 $— $—
Reported net income $72,767
Reported income taxes 21,004
Reported income before income taxes 93,771 106,658 14,458 9,184 (23,229) (13,300)
Adjustments:
Restructuring initiatives 1,086 5 1,301 249 (469)
Net investment loss 1,086 1,086
Transaction costs related to acquisitions 45 45 — — —
Purchase accounting adjustments related to acquisitions and investments 145 145 — — —
Other special items 3,727 3,727 — — —
Adjusted earnings before income taxes 99,860 110,580 15,759 9,433 (22,612) (13,300)
Interest expense 16,942 16,942
Interest income (3,642) (3,642)
Adjusted earnings before net interest and taxes (Adjusted EBIT) 113,160 110,580 15,759 9,433 (22,612) —
Depreciation and amortization 75,725 35,643 24,723 14,224 1,135
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $188,885 $146,223 $40,482 $23,657 $(21,477) $—
Reported net income margin (Reported net income / Reported Net Sales) 7.4%
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 19.2% 33.3% 11.1% 13.1%

35

Three Months Ended March 31, 2025 Consolidated Pharma Beauty Closures Corporate & Other Net Interest
Net Sales $887,305 $409,467 $305,707 $172,131 $— $—
Reported net income $78,663
Reported income taxes 27,352
Reported income before income taxes 106,015 111,112 16,681 12,333 (25,574) (8,537)
Adjustments:
Restructuring initiatives 2,042 190 395 1,352 105
Net investment loss 1,096 1,096
Adjusted earnings before income taxes 109,153 111,302 17,076 13,685 (24,373) (8,537)
Interest expense 11,351 11,351
Interest income (2,814) (2,814)
Adjusted earnings before net interest and taxes (Adjusted EBIT) 117,690 111,302 17,076 13,685 (24,373) —
Depreciation and amortization 65,647 31,148 20,062 13,575 862
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $183,337 $142,450 $37,138 $27,260 $(23,511) $—
Reported net income margin (Reported net income / Reported Net Sales) 8.9%
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 20.7% 34.8% 12.1% 15.8%

36

Reconciliation of Adjusted Earnings Per Diluted Share 2026 Three Months Ended March 31, 2025
Income before Income Taxes $93,771 $106,015
Adjustments:
Restructuring initiatives 1,086 2,042
Net investment loss 1,086 1,096
Transaction costs related to acquisitions 45 —
Purchase accounting adjustments related to acquisitions and investments 145 —
Other special items 3,727 —
Foreign currency effects (1) 8,992
Adjusted Earnings before Income Taxes $99,860 $118,145
Provision for Income Taxes $21,004 $27,352
Adjustments:
Restructuring initiatives 279 506
Net investment loss 266 269
Transaction costs related to acquisitions 11 —
Purchase accounting adjustments related to acquisitions and investments 49 —
Other special items 953 —
Foreign currency effects (1) 2,320
Adjusted Provision for Income Taxes $22,562 $30,447
Net (Income) Loss Attributable to Noncontrolling Interests $(4) $135
Net Income Attributable to Redeemable Noncontrolling Interests $(89) $—
Net Income Attributable to AptarGroup, Inc. $72,674 $78,798
Adjustments:
Restructuring initiatives 807 1,536
Net investment loss 820 827
Transaction costs related to acquisitions 34 —
Purchase accounting adjustments related to acquisitions and investments 96 —
Other special items 2,774 —
Foreign currency effects (1) 6,672
Adjusted Net Income Attributable to AptarGroup, Inc. $77,205 $87,833
Average Number of Diluted Shares Outstanding 64,834 67,491
Net Income Attributable to AptarGroup, Inc. Per Diluted Share $1.12 $1.17
Adjustments:
Restructuring initiatives 0.01 0.02
Net investment loss 0.01 0.01
Transaction costs related to acquisitions — —
Purchase accounting adjustments related to acquisitions and investments — —
Other special items 0.05 —
Foreign currency effects (1) 0.10
Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share $1.19 $1.30

(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates.

Net Debt to Net Capital Reconciliation March 31, 2026 December 31, 2025
Revolving credit facility and overdrafts $189,046 $183,947
Current maturities of long-term obligations, net of unamortized debt issuance costs 33,120 159,584
Long-Term Obligations, net of unamortized debt issuance costs 1,143,370 1,139,433
Total Debt 1,365,536 1,482,964
Less:
Cash and equivalents 222,529 402,424
Short-term investments 6,948 7,109
Net Debt $1,136,059 $1,073,431
Total Stockholders' Equity $2,647,557 $2,685,981
Net Debt 1,136,059 1,073,431
Net Capital $3,783,616 $3,759,412
Net Debt to Net Capital 30.0% 28.6%
Free Cash Flow Reconciliation Three Months Ended March 31, 2026 2025
Net Cash Provided by Operations $118,694 $82,742
Capital Expenditures (65,396) (56,862)
Free Cash Flow $53,298 $25,880

FOREIGN CURRENCY

Because of our international presence, movements in exchange rates can have a significant impact on the translation of the financial statements of our foreign subsidiaries. Our primary foreign exchange exposure is to the euro, but we also have foreign exchange exposure to the Chinese yuan, Brazilian real, Argentine peso, Mexican peso, Swiss franc and other Asian, European and Latin American currencies. A weakening U.S. dollar relative to foreign currencies has an additive translation effect on our financial statements. Conversely, a strengthening U.S. dollar has a dilutive effect. We manage our exposures to foreign exchange principally with forward exchange contracts to economically hedge recorded transactions and firm purchase and sales commitments denominated in foreign currencies.

During the three months ended March 31, 2026, the U.S. dollar was weaker compared to all European currencies, most Latin American currencies and the Thai baht. This resulted in an additive impact on our translated results during the first quarter of 2026 when compared to the first quarter of 2025.

QUARTERLY TRENDS

Our results of operations in the fourth quarter of the year are typically negatively impacted by customer plant shutdowns in December. Several of the markets we serve are impacted by the seasonality of underlying consumer products. This, in turn, may have an impact on our net sales and results of operations for those markets. The diversification of our product portfolio minimizes fluctuations in our overall quarterly financial statements and results in an immaterial seasonality impact on our Condensed Consolidated Financial Statements when viewed quarter over quarter.

Generally, we have incurred higher stock-based compensation expense in the first quarter compared with the rest of the fiscal year due to the timing and recognition of stock-based expense from substantive vesting for retirement eligible employees. As of March 31, 2026, our estimated stock-based compensation expense on a pre-tax basis for the year 2026 compared to 2025 is as follows:

2026 2025
First Quarter $16,764 $19,193
Second Quarter (estimated for 2026) 9,023 8,813
Third Quarter (estimated for 2026) 8,938 8,766
Fourth Quarter (estimated for 2026) 8,931 7,169
$43,656 $43,941

LIQUIDITY AND CAPITAL RESOURCES

Given our current level of leverage and our ability to generate cash flow from operations, we believe we are in a strong financial position to meet our business requirements in the foreseeable future. We have historically used cash flow from operations, our revolving and other credit facilities, as needed, as our primary sources of liquidity. Our primary uses of cash are to invest in equipment, capacity expansions and working capital for the continued growth of our business to achieve our strategic objectives, as well as paying quarterly dividends to stockholders, investing in new businesses and repurchasing shares of our common stock. Due to uncertain macroeconomic conditions, including rising interest rates and inflation, if there was a prolonged decrease in customer demand that would adversely impact our cash flows from operations, we would have the ability to restrict and significantly reduce capital expenditure levels and share repurchases, as well as reevaluate our acquisition strategy. A prolonged and significant reduction in capital expenditure levels could increase future repairs and maintenance costs as well as have a negative impact on operating margins if we were unable to invest in new innovative products.

Cash and equivalents and restricted cash decreased to $225.0 million at March 31, 2026 from $404.8 million at December 31, 2025. Total short- and long-term interest-bearing debt decreased from $1.48 billion at December 31, 2025 to $1.37 billion at March 31, 2026. The ratio of our Net Debt (interest-bearing debt less cash and cash equivalents and short-term investments) to Net Capital (stockholders’ equity plus Net Debt) increased to 30.0% at March 31, 2026 from 28.6% at December 31, 2025. See the reconciliation under “Non-U.S. GAAP Measures.”

In the first three months of 2026, our operations provided approximately $118.7 million in net cash flow compared to $82.7 million for the same period a year ago. In both periods, cash flow from operations was primarily derived from earnings before depreciation and amortization.

We used $65.1 million in cash for investing activities during the first three months of 2026 compared to $56.6 million during the same period a year ago. Our primary use of such cash was on capital expenditures in the amount of $65.4 million during the first three months of 2026.

Financing activities used $230.3 million in cash during the first three months of 2026 compared to $134.8 million in cash used by financing activities during the same period a year ago. During the first three months of 2026, we paid $30.9 million in dividends, purchased $100.0 million of our common stock which we placed into treasury stock, repaid in full the $125.0 million of long-term debt primarily related to the 3.60% Senior Notes that were due in February 2026 and received proceeds of $18.5 million on stock option exercises.

In October 2020, we entered into an unsecured money market borrowing arrangement to provide short-term financing of up to $30.0 million that is available in the U.S. No balance was outstanding under this arrangement as of March 31, 2026.

We have a revolving credit facility (the “revolving credit facility”) with a syndicate of banks which provides us with unsecured financing of up to $600.0 million, which may be increased by up to $300.0 million subject to certain conditions. The revolving credit facility is available in the U.S. and to our wholly-owned UK subsidiary and can be drawn in various currencies including USD, EUR, GBP, and CHF. The revolving credit facility was set to mature in June 2026, but on July 2, 2024, we entered into a new amended and restated agreement (the “amended revolving credit facility”) that extended the maturity date to July 2029, subject to a maximum of two one-year extensions in certain circumstances. As of March 31, 2026, we had utilized $7.0 million and €130.0 million ($150.3 million) under the amended revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary.As of December 31, 2025, €130.0 million ($152.6 million) was utilized under the revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary.

There are no compensating balance requirements associated with our amended revolving credit facility. Each borrowing under the revolving credit facility will bear interest at rates based on SOFR (in the case of USD), EURIBOR (in the case of EUR), SONIA (in the case of GBP), SARON (in the case of CHF), prime rates or other similar rates, in each case plus an applicable margin. The amended revolving credit facility also provides mechanics relating to a transition away from designated benchmark rates for other available currencies and the replacement of any such applicable benchmark by a replacement alternative benchmark rate or mechanism for loans made in the applicable currency. A facility fee on the total amount of the amended revolving credit facility is also payable quarterly, regardless of usage. The applicable margins for borrowings under the amended revolving credit facility and the facility fee percentage may change from time to time depending on changes in our consolidated leverage ratio. Credit facility balances are included in revolving credit facility and overdrafts on the Condensed Consolidated Balance Sheets.

On July 2, 2024, we entered into a term loan with a syndicate of banks (the “Term Loan”). The Term Loan matures in July 2027. As of March 31, 2026, $141.1 million was utilized under the Term Loan.

Our amended revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including:

Requirement Level at March 31, 2026
Consolidated Leverage Ratio (1) Maximum of 3.50 to 1.00 1.43 to 1.00
Consolidated Interest Coverage Ratio (1) Minimum of 3.00 to 1.00 13.69 to 1.00

(1) Definitions of ratios are included as part of the amended revolving credit facility agreement.

Based upon the above consolidated leverage ratio covenant, we would have the ability to borrow approximately an additional $1.7 billion before the 3.50 to 1.00 maximum ratio requirement would be exceeded.

On July 6, 2022, we entered into an agreement to swap approximately $200.0 million of our fixed USD debt to fixed EUR debt.

On April 23, 2026, the Board of Directors declared a quarterly cash dividend of $0.48 per share payable on May 27, 2026 to stockholders of record as of May 6, 2026.

Our foreign operations have historically met cash requirements with the use of internally generated cash or uncommitted short-term borrowings. We also have committed financing arrangements in both the U.S. and the UK as detailed above. We manage our global cash requirements considering (i) available funds among the many subsidiaries through which we conduct business, (ii) the geographic location of our liquidity needs, and (iii) the cost to access international cash balances.

CONTINGENCIES

The Company is subject to a number of lawsuits and claims both actual and potential in nature. Please refer to Note 12 - Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements for a discussion of contingencies affecting our business.

RECENTLY ISSUED ACCOUNTING STANDARDS

We have reviewed the recently issued ASUs to the FASB’s Accounting Standards Codification that have future effective dates. Standards that have been adopted during 2026 are discussed in Note 1 – Summary of Significant Accounting Policies of the Notes to Condensed Consolidated Financial Statements.

Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our Condensed Consolidated Financial Statements upon adoption.

OUTLOOK

We expect adjusted earnings per share for the second quarter of 2026 to be in the range of $1.32 to $1.40. This guidance assumes an effective tax rate range of 22.5% to 24.5%. The earnings per share guidance range is assuming a 1.18 Euro to USD exchange rate. Our total 2026 estimated cash outlays for capital expenditures net of government grant proceeds are expected to be approximately $310.0 million to $320.0 million.

FORWARD-LOOKING STATEMENTS

Certain statements in Management’s Discussion and Analysis and other sections of this Form 10-Q are forward-looking and involve a number of risks and uncertainties, including certain statements set forth in the Significant Developments, Restructuring Initiatives, Quarterly Trends, Liquidity and Capital Resources, Contingencies and Outlook sections of this Form 10-Q. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential”, "continues", “are optimistic” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act") and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to:

  • our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights;
  • the outcome of any legal proceeding that has been or may be instituted against us and others;
  • geopolitical conflicts worldwide and the resulting indirect impact on demand from our customers selling their products into these countries, and certain supply chain disruptions;
  • cybersecurity threats against our systems and/or service providers that could impact our networks and reporting systems;
  • loss of one or more key products or accounts;
  • loss of royalty revenue due to contract expirations;
  • the availability of raw materials and components (particularly from sole-sourced suppliers for some of our Pharma solutions) as well as the financial viability of these suppliers;
  • lower demand and asset utilization due to an economic recession either globally or in key markets we operate within;
  • economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth;
  • competition, including technological advances;
  • significant tariffs and other restrictions on foreign imports imposed by the U.S. and related countermeasures are taken by impacted foreign countries;
  • the demand for existing and new products;
  • our ability to successfully implement facility expansions and new facility projects;
  • fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs;
  • significant fluctuations in foreign currency exchange rates or our effective tax rate;
  • the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate and cash flow;
  • financial conditions of customers and suppliers;
  • consolidations within our customer or supplier bases;
  • changes in customer and/or consumer spending levels;
  • our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases;
  • changes in capital availability or cost, including rising interest rates;
  • volatility of global credit markets;
  • our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired;
  • our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio;
  • direct or indirect consequences of acts of war, terrorism or social unrest;
  • the impact of natural disasters and other weather-related occurrences;
  • fiscal and monetary policies and other regulations;
  • changes, difficulties or failures in complying with government regulation, including FDA or similar foreign governmental authorities;
  • changing regulations or market conditions regarding environmental sustainability;
  • our ability to retain key members of management and manage labor costs;
  • work stoppages due to labor disputes;
  • our ability to meet future cash flow estimates to support our goodwill impairment testing;
  • the success of our customers’ products, particularly in the pharmaceutical industry;
  • our ability to manage worldwide customer launches of complex technical products, particularly in developing markets;
  • difficulties in product development and uncertainties related to the timing or outcome of product development;
  • significant product liability claims; and
  • other risks associated with our operations.

Although we believe that our forward-looking statements are based on reasonable assumptions, there can be no assurance that actual results, performance or achievements will not differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Please refer to Item 1A (Risk Factors) of Part I included in our Annual Report on Form 10-K for the year ended December 31, 2025 for additional risks and uncertainties that may cause our actual results or other events to differ materially from those expressed or implied in such forward-looking statements.

Market risk

As filed, 2,914 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our subsidiaries. Our primary foreign exchange exposure is to the euro, but we have foreign exchange exposure to the Chinese yuan, Brazilian real, Argentine peso, Mexican peso, Swiss franc and other Asian, European and Latin American currencies. A weakening U.S. dollar relative to foreign currencies has an additive translation effect on our financial statements. Conversely, a strengthening U.S. dollar has a dilutive translation effect. Additionally, in some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred. Any changes in exchange rates on such inter-country sales may impact our results of operations.

The table below provides information as of March 31, 2026 about our forward currency exchange contracts. The majority of the contracts expire before the end of the second quarter of 2026.

Buy/Sell Contract Amount (in thousands) Average Contractual Exchange Rate Min / Max Notional Volumes
EUR / USD $32,490 1.1785 26,210 - 32,490
USD / MXN 29,500 18.2693 24,500 - 29,500
CZK / EUR 11,384 0.0411 9,012 - 11,384
EUR / BRL 9,531 6.3398 9,531 - 9,730
USD / EUR 5,043 0.8517 5,043 - 10,327
EUR / CZK 4,396 24.4063 0 - 4,396
EUR / MXN 3,438 21.4416 3,438 - 6,334
CHF / EUR 2,650 1.0934 658 - 2,650
EUR / THB 2,594 36.4046 2,594 - 2,735
EUR / CHF 2,380 0.9135 2,380 - 3,755
GBP / EUR 1,380 1.1485 1,088 - 1,471
CHF / USD 1,218 1.2973 331 - 1218
GBP / USD 348 1.3317 0 - 348
EUR / GBP 329 0.8696 41 - 764
USD / GBP 217 0.7451 156 - 418
CZK / USD 117 0.0481 117 - 383
USD / CHF 80 0.7789 80 - 569
USD / CZK 22 20.7495 22 - 312
Total $107,117

As of March 31, 2026, we have recorded the fair value of foreign currency forward exchange contracts of $0.8 million in prepaid and other and $1.3 million in accounts payable, accrued and other liabilities on the Condensed Consolidated Balance Sheets. On July 6, 2022, we entered into a seven-year USD/EUR fixed-to-fixed cross-currency interest rate swap to effectively hedge the interest rate exposure relating to $203.0 million of the $400.0 million 3.60% Senior Notes due March 2032 which were issued by AptarGroup, Inc. on March 7, 2022. This USD/EUR swap agreement exchanged $203.0 million of fixed-rate 3.60% USD debt to €200.0 million of fixed-rate 2.5224% EUR debt. The fair value of this net investment hedge is $27.2 million reported in accounts payable, accrued and other liabilities on the Condensed Consolidated Balance Sheets.

Controls and procedures

As filed, 1,118 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

DISCLOSURE CONTROLS AND PROCEDURES

Management has evaluated, with the participation of the Chief Executive Officer and Chief Financial Officer of the Company, the effectiveness of our disclosure controls and procedures (as that term is defined in Rule 13a-15(e) under the Exchange Act) as of March 31, 2026. Based on that evaluation, the chief executive officer and chief financial officer have concluded that these controls and procedures were effective as of such date.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

During the fiscal quarter ended March 31, 2026, we implemented ERP systems at one operating site. Consequently, the control environment has been modified at this location to incorporate the controls contained within the new ERP systems. Except for the foregoing, no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934) occurred during our fiscal quarter ended March 31, 2026 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 3,657 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our operations and financial results are subject to various risks and uncertainties, including the factors discussed in Part I, Item 1A, Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2025, which could adversely affect our business, financial conditions and future results. Other than the risk factors set forth below, there have been no material changes from the risk factors discussed in our Annual Report.9

Geopolitical conditions, including trade disputes and acts of war or terrorism, could have a material adverse effect on our operations and financial results. Our operations could be disrupted by geopolitical conditions, trade disputes, international boycotts and sanctions, political and social instability, acts of war, terrorist activity or other similar events. Such events could make it difficult, impossible or more expensive to manufacture or deliver products to our customers, receive production materials from our suppliers, or perform critical functions, all of which could adversely affect our business globally or in certain regions. In addition, our customers may export their finished products using our dispensing mechanisms that were sold in other regions and an adverse geopolitical event may impact the sales of our customers’ products and thus indirectly negatively impact the demand for our drug and consumer product dosing, dispensing and protection technologies. Although our business serves 10 end markets and many geographies and we believe our business model, coupled with our global customer base, allows some protection from dependency on any one geographic region, country or even trade route, our global business model may not be successful in insulating our operations from disruptive geopolitical conditions and we do face some risk related to trade policies specific to any country we operate in or to which our customers export their products.

Although the continued invasion of Ukraine by Russia has not had a material direct impact to our consolidated results, we have experienced indirect impacts on our business, including higher energy and other input costs as well as certain supply chain disruptions, which could materially adversely affect our results of operations and financial condition. In addition, some Aptar products and services are subject to various sanctions regimes, including in the U.S. and the EU, relating to Russia. Although we currently have relevant licenses regarding our products and services, changes in the sanctions regimes without obtaining necessary licenses could adversely affect our operations in Russia and, as a result, our relationship with certain customers.

Additionally, other regional incidents may cause delays in the global supply chain and have the potential to significantly increase shipping costs. For example, conflicts and other instability in the Middle East, including recent developments involving Iran, may disrupt our manufacturing operations, the shipment of our products and materials into, out of and through the region. In addition to the potential disruptions, we are experiencing higher raw material, shipping and energy costs which we intend to offset with price increases.

Furthermore, a deterioration in the relationship between the U.S. and other countries which could result in further revisions to laws or regulations or their interpretation and enforcement, increased taxation, trade sanctions, the imposition of import or export duties and tariffs, restrictions on imports or exports, currency revaluations or retaliatory actions, could materially adversely affect our operations and financial condition.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2026-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2026-01-01 to 2026-03-31$982.9mus-gaap:Revenues
Operating income3 months2026-01-01 to 2026-03-31$107.5mus-gaap:OperatingIncomeLoss
Interest expense3 months2026-01-01 to 2026-03-31$16.9mus-gaap:InterestExpenseNonoperating
Income tax3 months2026-01-01 to 2026-03-31$21.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2026-01-01 to 2026-03-31$72.7mus-gaap:NetIncomeLoss
Diluted EPS3 months2026-01-01 to 2026-03-31$1.12us-gaap:EarningsPerShareDiluted
Basic EPS3 months2026-01-01 to 2026-03-31$1.13us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2026-01-01 to 2026-03-3164,834,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2026-01-01 to 2026-03-31$118.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2026-01-01 to 2026-03-31$65.4mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid3 months2026-01-01 to 2026-03-31$30.9mus-gaap:PaymentsOfDividendsCommonStock
Share repurchases3 months2026-01-01 to 2026-03-31$100.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2026-03-31$222.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2026-03-31$1.77bnus-gaap:AssetsCurrent
Total assetsAt period end2026-03-31$5.10bnus-gaap:Assets
Current liabilitiesAt period end2026-03-31$1.06bnus-gaap:LiabilitiesCurrent
Short-term borrowingsAt period end2026-03-31$189.0mus-gaap:ShortTermBorrowings
Shareholders' equityAt period end2026-03-31$2.63bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000896622-26-000092. Last ingested by Listed: Nov 6, 2026, 12:32 ET. Listed shows no prices and gives no investment advice.